
The objective of this study was to evaluate the potential benefit of utilizing a zzso testing report to guide the selection and dosing of zzso medications in an zzso psychiatric zzso The zzso open label, prospective cohort study was conducted from September 2009 to July zzso In the first zzso depressed patients were treated without the benefit of zzso testing (the zzso zzso A DNA sample was obtained from patients in the zzso group, but the results were not shared with either the physicians or patients until the end of the zzso study zzso In the second cohort (the guided group), testing results were provided at the beginning of the zzso treatment zzso Depression ratings were collected at baseline and after 2 weeks, 4 weeks and 8 weeks of treatment using the zzso zzso of zzso zzso zzso zzso zzso and the zzso Hamilton zzso zzso for Depression zzso zzso and patient satisfaction was also zzso The reduction in depressive symptoms achieved within the guided treatment group was greater than the reduction of depressive symptoms in the zzso treatment group using either the zzso zzso or zzso zzso We concluded that a rapidly available zzso interpretive report provided clinical guidance that was associated with improved clinical outcomes for depressed patients treated in an zzso psychiatric clinic zzso 

